The European Patent Office (EPO) has published patent application EP4495059A2, filed by Osaka University, detailing the use of silicon nanoparticles for treating kidney diseases. The application includes International Patent Classification (IPC) codes related to pharmaceutical compositions, drug delivery systems, and therapeutic applications for kidney and cardiovascular conditions, as well as antioxidant effects.

This publication represents a new patent application and does not impose immediate compliance obligations on regulated entities. However, it signifies potential future developments in therapeutic treatments for kidney diseases, which may be of interest to pharmaceutical and biotechnology companies operating within the EU. Compliance officers in these sectors should monitor the progress of this and similar patent applications.